FDA’s Center for Tobacco Products published the actions it plans to take in response to an external evaluation commissioned last year from an independent panel of evaluators working through the Reagan-Udall Foundation.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
